497 related articles for article (PubMed ID: 32793604)
1. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors.
Lei Q; Wang D; Sun K; Wang L; Zhang Y
Front Cell Dev Biol; 2020; 8():672. PubMed ID: 32793604
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.
Liu J; Chen Z; Li Y; Zhao W; Wu J; Zhang Z
Front Pharmacol; 2021; 12():731798. PubMed ID: 34539412
[TBL] [Abstract][Full Text] [Related]
3. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
[TBL] [Abstract][Full Text] [Related]
4. Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy.
Luo K; Liu S; Shen X; Xu J; Shi C; Chao Y; Wen Z; Zhang K; Wang R; Liu B; Jiang Y
Front Cell Dev Biol; 2022; 10():1003656. PubMed ID: 36467413
[No Abstract] [Full Text] [Related]
5. Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.
Su CW; Hou MM; Huang PW; Chou YC; Huang BS; Tseng JH; Hsu CW; Chang TC; Lin SM; Lin CC
Am J Cancer Res; 2022; 12(4):1606-1620. PubMed ID: 35530291
[TBL] [Abstract][Full Text] [Related]
6. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.
Liu Y; Xu Y; Cheng X; Lin Y; Jiang S; Yu H; Zhang Z; Lu L; Zhang X
Front Immunol; 2022; 13():862084. PubMed ID: 35493449
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy.
Sun Y; Mo L; Hu X; Yu D; Xie S; Li J; Zhao Z; Fang X; Ye M; Qiu L; Tan W; Yang Y
ACS Nano; 2022 Dec; 16(12):21129-21138. PubMed ID: 36484532
[TBL] [Abstract][Full Text] [Related]
8. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review).
Ma X; Wu J; Wang B; Liu C; Liu L; Sun C
Int J Oncol; 2022 Nov; 61(5):. PubMed ID: 36129152
[TBL] [Abstract][Full Text] [Related]
10. Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor.
Zhao J; Dong J; Deng C; Zhang Q; Sun S; Li H; Bai Y; Deng H
Oncoimmunology; 2023; 12(1):2265703. PubMed ID: 37808405
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
Zuazo M; Gato-Cañas M; Llorente N; Ibañez-Vea M; Arasanz H; Kochan G; Escors D
Ann Transl Med; 2017 Oct; 5(19):385. PubMed ID: 29114543
[TBL] [Abstract][Full Text] [Related]
12. Automated Analysis of PD1 and PDL1 Expression in Lymph Nodes and the Microenvironment of Transmissible Tumors in Tasmanian Devils.
Russell GG; Palmieri C; Darby J; Morris GP; Fountain-Jones NM; Pye RJ; Flies AS
Immunol Invest; 2023 Nov; 52(6):661-680. PubMed ID: 37267050
[TBL] [Abstract][Full Text] [Related]
13. Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study.
Sun Y; Jiang L; Wen T; Guo X; Shao X; Qu H; Chen X; Song Y; Wang F; Qu X; Li Z
Front Pharmacol; 2021; 12():670900. PubMed ID: 34489691
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
[TBL] [Abstract][Full Text] [Related]
15. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy.
Weidhaas J; Marco N; Scheffler AW; Kalbasi A; Wilenius K; Rietdorf E; Gill J; Heilig M; Desler C; Chin RK; Kaprealian T; McCloskey S; Raldow A; Raja NP; Kesari S; Carrillo J; Drakaki A; Scholz M; Telesca D
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35115362
[TBL] [Abstract][Full Text] [Related]
16. Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain.
Zhang A; Wang S; Sun Y; Zhang Y; Zhao L; Yang Y; Zhang Y; Xu L; Lei Y; Du J; Chen H; Duan L; He M; Shi L; Liu L; Wang Q; Hu L; Zhang B
Exp Hematol Oncol; 2023 Sep; 12(1):85. PubMed ID: 37777797
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
Guo L; Bodo J; Durkin L; Hsi ED
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
[TBL] [Abstract][Full Text] [Related]
18. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
19. Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment.
Wang YL; Gong Y; Lv Z; Li L; Yuan Y
J Cancer; 2021; 12(6):1698-1707. PubMed ID: 33613757
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis.
Xian F; Wu J; Zhong L; Xu G
Medicine (Baltimore); 2023 Mar; 102(10):e33204. PubMed ID: 36897735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]